Evidence map›Paper›PMID 41869410›Full record

ReviewInternational journal of nanomedicine2026

Targeted Delivery of Nucleic Acid Therapeutics: Emerging Carriers and Applications in Common Metabolic and Inflammatory Diseases.

Xiyuan Lin, Li Chen, Keran Jia, Shengbiao Li, Qiuhong Li, Jingyan Yi, Jinshan Xing

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiyuan Lin *Department of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Key Laboratory of Medical Electrophysiology, Ministry of Education, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Li Chen *Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Keran Jia *Department of Health Services and Management, School of Health Care Technology, Chengdu Neusoft University, Chengdu, Sichuan, 610000, People's Republic of China.
Shengbiao LiDepartment of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Key Laboratory of Medical Electrophysiology, Ministry of Education, Institute of Cardiovascular Research, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Qiuhong LiDepartment of Histology and Embryology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.
Jingyan YiDepartment of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Key Laboratory of Medical Electrophysiology, Ministry of Education, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.ORCID 0000-0002-7146-1360
Jinshan XingDepartment of Neurosurgery, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in genomics and molecular biology have accelerated the development of nucleic acid-based therapeutics. To optimize their clinical efficacy, various delivery systems-including lipid nanoparticles, polymeric nanomaterials, inorganic nanoparticles (NPs), extracellular vesicles (EVs), viral vectors, protein carriers, and nucleic acid conjugates-have been explored to improve stability, cellular uptake, and bioavailability. This review provides an overview of the current state of nucleic acid therapeutics, focusing on their classification, delivery strategies, and applications in metabolic and inflammatory diseases. Emphasis is placed on the mechanisms of action, targeted delivery approaches, and the existing challenges these systems face. Literature was sourced from PubMed and Web of Science, relevance to the topic, and publication timeline (2020-2025). The aim is to propose insights into the optimization of nucleic acid drugs and the development of novel delivery systems, offering new perspectives for the treatment of complex diseases.

Indexed as

Drug Delivery SystemsInflammationMetabolic DiseasesNucleic AcidsAnimalsDrug CarriersHumansNanoparticlesDrug CarriersNucleic Acidsdelivery systemsinflammatory diseasesmetabolic diseasesnucleic acid therapeutics

Identifiers

PMID41869410
PMCPMC13003636

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.